Skip to main navigation
Madrigal Pharmaceuticals Madrigal Pharmaceuticals.
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Resmetirom
      • Clinical Trials
      • Publications
  • NASH
    • Overview
    • Patient and HCP Perspectives
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
    • Email Alerts
  • Careers
    • Join the team
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
Search
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Resmetirom
      • Clinical Trials
      • Publications
  • NASH
    • Overview
    • Patient and HCP Perspectives
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
    • Email Alerts
  • Careers
    • Join the team
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
  • Overview
  • Press Releases
  • Events and Presentations
  • Financials and Filings
  • Stock Information
  • Corporate Governance
  • FAQs
  • Email Alerts

Madrigal press releases are available below. Search them by keyword or browse by date.

September 28, 2023
Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering
September 28, 2023
Madrigal Pharmaceuticals Announces Proposed Public Offering
September 14, 2023
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 13, 2023
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
September 11, 2023
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer
August 8, 2023
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
July 17, 2023
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
June 30, 2023
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
June 22, 2023
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
June 6, 2023
Madrigal Pharmaceuticals Supports International NASH Day on June 8
Pagination
  • Current page 1
  • Page 2
  • Next page

We are conducting a late-stage clinical development program to demonstrate the benefit of resmetirom to patients with NASH and liver fibrosis.

Learn More
Madrigal Pharmaceuticals. Logo

Madrigal Pharmaceuticals

200 Barr Harbor Drive,
Suite 200

West Conshohocken,
Pennsylvania 19428

  • About Us
  • Our Programs
  • NASH
  • Investors & Media
  • Careers
  • Contact
Madrigal Pharmaceuticals
  • Terms of Use
  • Privacy
  • Cookies
  • CA COMPLIANCE
©2023 Madrigal Pharmaceuticals. All rights reserved.